RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

When you think about it, Lilly is still the most obvious choice as a BP partner. Not only have they done a lot of work with AMPA upmodulation for many years, their biarylpropylsulfonamide family of compounds is likely still experiencing excitotoxicity related troubles. In Dr. Rogers' SHM presentation several years ago, he made it sound like Lilly's compound family was doomed to having very high seizure risk, due to its extremely strong action at the receptor binding site. So Lilly could probably use an alternate approach chemistry-wise.

Lilly also has a strong interest in ADHD with Strattera. And of course Lilly (along with Glaxo) has been trying to overturn Cortex/UCI's broad use patent in Europe for years, so far unsuccessfully. When the final BP bids are tallied, it would be hard to imagine Lilly not being involved, although to date they have apparently remained stubbornly aloof.